心力衰竭治疗的新药与非药物治疗研究进展

Progress of New Drug and Non-drug Therapy about Heart Failure

简述心力衰竭治疗的新药与非药物治疗最新的试验与进展情况。在药物领域中,Omecamtiv mecarbil呈剂量依赖性地提高了左室射血时间和每搏输出量,同时伴有心率的轻度下降,且具有良好的安全性;伊伐布雷定可能有助于逆转慢性心力衰竭患者的左室重构、改善其生活质量;Mydicar可恢复SERCA2a蛋白的水平,调节钙循环和提高心脏收缩性;非药物领域中,心脏收缩力调节起搏对心肌进行绝对不应期刺激以加强心肌收缩力,改善心功能不全;干细胞移植疗法可能的机制是,移植的干细胞在局部微环境的诱导下可以分化为心肌细胞、血管内皮细胞、平滑肌细胞等,增加心肌收缩力。

This article reviewed the progress and key trials relevant to the treatment of heart failure in the new drug and non-drug treatment.in the field of medication therapy ,Omecamtiv mecarbil is dependent of dose and can improve time of the left ventricular ejection and stroke volume ,at the same time it declines heart rate mildly and has good security.Ivabradine maybe contribute to reversing left ventricular refactoring and improve quality of life in pa-tients of chronic heart failure .Mydicar can recover SERC 2 a protein level ,regulate calcium circumlation and improve cardiac contractility.In the field of non-drug,cardiac contractility modulation stimulates cardiac muscle in absolute refractory period to strengthen the cardiac contraction and improve the cardiac insufficiency .Stem cell transplantation therapy：mechanism is possible that the transplanted stem cells in the local microenvironment can differentiate into myocardial cells under the induction of endothelial cells , smooth muscle cells , increase the myocardial contraction force.